From: Multidisciplinary intervention for adverse events associated with ATZ + BEV therapy: a case report
Day0 | |||||
WBC | 7800 | /μL | AST | 31 | U/L |
RBC | 405 | ×103/μL | ALT | 60 | U/L |
Hb | 10.7 | g/dL | ALP | 197 | U/L |
Ht | 33.5 | % | γ-GTP | 77 | U/L |
Plt | 501 | ×103/μL | T-Bil | 0.4 | mg/dL |
Lympho | 33.5 | % | LDH | 220 | U/L |
AFP | 1 | ng/mL | Alb | 2.8 | g/dL |
PIVKA-II | 923 | mAU/mL | Na | 139 | mEq/L |
FT4 | 1.24 | ng/dL | K | 4.3 | mEq/L |
FT3 | 3.14 | pg/mL | Cl | 105 | mEq/L |
TSH | 2.34 | mIU/L | BUN | 25 | mg/dL |
Cortisol | 15.4 | μg/dL | Cre | 1.13 | mg/dL |
ACTH | 19.7 | pg/mL | eGFR | 49.5 | ml/min |
Day22 | |||||
WBC | 6800 | /μL | AST | 43 | U/L |
RBC | 340 | ×103/μL | ALT | 72 | U/L |
Hb | 9.1 | g/dL | ALP | 144 | U/L |
Ht | 28.4 | % | γ-GTP | 83 | U/L |
Plt | 473 | ×103/μL | T-Bil | 0.5 | mg/dL |
Lympho | 24.5 | % | LDH | 213 | U/L |
Cortisol | 15.5 | μg/dL | Alb | 2.5 | g/dL |
ACTH | 26.1 | pg/mL | Na | 131 | mEq/L |
K | 4.6 | mEq/L | |||
Cl | 100 | mEq/L | |||
BUN | 16 | mg/dL | |||
Cre | 0.81 | mg/dL | |||
eGFR | 71.3 | ml/min |